Advances in the models for predicting the risk of liver cancer during antiviral therapy in patients with chronic hepatitis B / 临床肝胆病杂志
Journal of Clinical Hepatology
;
(12): 433-436, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-873417
ABSTRACT
Hepatitis B virus infection is one of the primary causes of liver cirrhosis and liver cancer. The use of antiviral drugs significantly reduces the risk of liver cancer in patients with chronic hepatitis B (CHB), but some of the patients who receive antiviral drugs for a long time still develop liver cancer. Therefore, it is necessary to early identify and predict the risk of liver cancer in such patients. Currently, several models for predicting the risk of liver cancer during antiviral therapy in CHB patients have been developed based on the risk factors such as liver cirrhosis, age, sex, liver stiffness, virology, serological markers, alcohol consumption, and history of diabetes, including REACH-B, PAGE-B, mPAGE-B, APA-B, CAMD, AASL, and REAL-B. This article reviews the research advances in the models for predicting the risk of liver cancer during antiviral therapy in CHB patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Etiology study
/
Prognostic study
/
Risk factors
Language:
Chinese
Journal:
Journal of Clinical Hepatology
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS